Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06370780 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Exploring, Predicting, and Intervening on Long-term Viral Suppression Electronically

Study acronym: EPI-LoVE
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Eligibility criteria expanded, about 10 words
    • Site details revised
  2. Site contact updated
    • Collaborators: 4 to 5
    v9
  3. Site contact updatedv8
  4. Primary and study completion dates: Apr 30, 2025 to Apr 30, 2028
    • Site contact updated
    v7
  5. Site contact updatedv6
Show 4 earlier versionsHide 4 earlier versions
  1. Site contact updatedv5
  2. Site contact updatedv4
  3. Phase: Not specified to Not applicable
    • Primary completion date: Feb 9, 2027 to Apr 30, 2025
    • Study completion date: Oct 9, 2028 to Apr 30, 2025
    • Study arms: 0 to 1
    v3
  4. Study description expanded, about 188 wordsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Despite the widespread availability of effective antiretroviral therapy (ART) in the United States, there remains significant numbers of people living with HIV (PLWH) who fail to achieve and or maintain viral suppression (VS). Disparities persist with the lowest levels of VS among Black individuals, people who use drugs, youth ages 18-24 and people residing in rural areas. Investigators will examine the syndemics underlying these outcomes including substance use, mental health, and barriers to HIV care including racial discrimination, stigma and rural isolation.
Trial Details
NCT Number NCT06370780
Lead Sponsor University of California, Los Angeles
Collaborators: Florida State University, University of California, Irvine, University of North Carolina, Chapel Hill, AIDS Healthcare Foundation, National Institute of Allergy and Infectious Diseases (NIAID)
Conditions
(from sponsor)		 HIV Infections
Related terms HIV Infections
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov